Detalhe da pesquisa
1.
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med
; 384(13): 1216-1226, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789010
2.
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
N Engl J Med
; 380(6): 528-538, 2019 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30726689
3.
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
N Engl J Med
; 379(1): 11-21, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29972753
4.
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
Antimicrob Agents Chemother
; 63(7)2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30988146
5.
A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
Clin Infect Dis
; 67(5): 657-666, 2018 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29518178
6.
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
Clin Infect Dis
; 66(8): 1222-1229, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29281036
7.
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358292
8.
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
Antimicrob Agents Chemother
; 62(5)2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29530858
9.
Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother
; 61(6)2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28373199
10.
Single-dose oritavancin in the treatment of acute bacterial skin infections.
N Engl J Med
; 370(23): 2180-90, 2014 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24897083
11.
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Clin Infect Dis
; 60(2): 254-62, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25294250
12.
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Antimicrob Agents Chemother
; 60(3): 1546-55, 2015 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26711747
13.
Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
Clin Infect Dis
; 58 Suppl 1: S43-50, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24343832
14.
A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.
J Hepatol
; 60(5): 920-7, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24434503
15.
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.
Antimicrob Agents Chemother
; 58(11): 6518-27, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25136015
16.
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
BMC Infect Dis
; 14: 289, 2014 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24884578
17.
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
J Antimicrob Chemother
; 67(6): 1496-502, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22416054
18.
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection.
Antimicrob Agents Chemother
; 55(12): 5790-7, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21947389
19.
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
J Med Microbiol
; 69(4): 625-630, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32195649
20.
Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
Stroke
; 40(11): 3532-40, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19696423